Highly concentrated drug particles, formulations, suspensions and uses thereof

• US 20100092566A1
• Filed: 10/14/2009
• Published: 04/15/2010
• Est. Priority Date: 10/15/2008
• Status: Abandoned Application

• Current Assignee: Intarcia Therapeutics, Inc.
• Original Assignee: Intarcia Therapeutics, Inc.
• Inventors: Mercer, Ryan D., Alessi, Thomas R., Rohloff, Catherine M., Yang, Bing
• Application Number:
  US12/587,946
• Publication Number:
  US 20100092566A1
• Time in Patent Office: Days
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1623 Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• CPC Class Codes: A61K 9/1682 Processes
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.

Claims

1. A particle formulation comprising,

about 25 wt % to about 80 wt % drug;

and

about 75 wt % to about 20 wt % of one or more additional component, wherein the ratio of drug;

additional component is between about 1;

1 to about 5;

1.

2. The particle formulation of claim 1, wherein the drug comprises about 40 wt % to about 75 wt % and the one or more additional component comprises about 60 wt % to about 25 wt %.

3. The particle formulation of claim 1, wherein the one or more additional component is selected from the group consisting of antioxidant, carbohydrate, and buffer.

4. The particle formulation of claim 3, wherein the one or more additional component comprises an antioxidant and the antioxidant is selected from the group consisting of cysteine, methionine, and tryptophan.

5. The particle formulation of claim 4, wherein the antioxidant is methionine.

6. The particle formulation of claim 3, wherein the one or more additional component comprises a buffer and the buffer is selected from the group consisting of citrate, histidine, succinate, and mixtures thereof.

7. The particle formulation of claim 6, wherein the buffer is a citrate.

8. The particle formulation of claim 3, wherein the one or more additional component comprises a carbohydrate and the carbohydrate is a disaccharide.

9. The particle formulation of claim 8, wherein the disaccharide is selected from the group consisting of lactose, sucrose, trehalose, cellobiose, and mixtures thereof.

10. The particle formulation of claim 9, wherein the dissaccharide is sucrose.

11. The particle formulation of claim 3, wherein the one or more additional component comprises antioxidant, carbohydrate, and buffer, and the ratio of drug:

antioxidant;

carbohydrate;

buffer is between about 2-20;

1-5;

1-5;

1-10.

12. The particle formulation of claim 1, wherein the particle formulation is a spray dried preparation of particles.

13. The particle formulation of claim 1, wherein the drug is a protein.

14. The particle formulation of claim 13, wherein the protein is an interferon.

15. The particle formulation of claim 13, wherein the protein is an incretin mimetic.

16. The particle formulation of claim 15, wherein the incretin mimetic is a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1, or an analogue of GLP-1.

17. The particle formulation of claim 16, wherein the incretin mimetic is GLP-1(7-36)amide.

18. The particle formulation of claim 15, wherein the incretin mimetic is exenatide, a derivative of exenatide, or an analogue of exenatide.

19. The particle formulation of claim 18, wherein the incretin mimetic is exenatide.

20. The particle formulation of claim 13, wherein the protein is selected from the group consisting of exenatide, PYY, GLP-1(7-36)amide, oxyntomodulin, GIP and leptin.

21. The particle formulation of claim 13, wherein the protein is selected from the group consisting of recombinant antibodies, antibody fragments, humanized antibodies, single chain antibodies, monoclonal antibodies, and avimers.

22. The particle formulation of claim 13, wherein the protein is selected from the group consisting of human growth hormone, epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, transforming growth factor, and nerve growth factor.

23. The particle formulation of claim 13, wherein the protein is a cytokine.

24. The particle formulation of claim 1, wherein particles of the particle formulation are particles of between about 2 microns to about 10 microns.

25. A suspension formulation comprising,

a particle formulation of claim 1;

and

a non-aqueous, single-phase suspension vehicle comprising one or more polymer and one or more solvent;

wherein the suspension vehicle exhibits viscous fluid characteristics, and the particle formulation is homogeneously dispersed in the vehicle.

26. The suspension formulation of claim 25, wherein the one or more polymer is a polymer comprising pyrrolidones.

27. The suspension formulation of claim 26, wherein the one or more polymer is polyvinylpyrrolidone.

28. The suspension formulation of claim 25, wherein the one or more solvent is selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof.

29. The suspension formulation of claim 25, wherein the suspension vehicle consists essentially of one or more polymer and one or more solvent.

30. The suspension formulation of claim 29, wherein the one or more solvent consists essentially of benzyl benzoate.

31. The suspension formulation of claim 29, wherein the one or more polymer consists essentially of polyvinylpyrrolidone.

32. The suspension formulation of claim 29, wherein the suspension vehicle consists essentially of benzyl benzoate and a polymer comprising pyrrolidones.

33. The suspension formulation of claim 32, wherein the suspension vehicle is about 50% solvent and about 50% polymer.

34. The suspension formulation of claim 25, wherein the suspension vehicle has a viscosity of about 15,000 poise, plus or minus about 3,000 poise.

35. An osmotic delivery device, comprising the suspension formulation of claim 25.

36. The osmotic delivery device of claim 35, wherein the osmotic delivery device comprises a reservoir having the dimensions of between about 35 mm and about 20 mm in length and about 8 mm and about 3 mm in diameter.

37. The osmotic delivery device of claim 36, wherein the reservoir has the dimensions of between about 30 mm and about 25 mm in length and about 4 mm to about 3.8 mm in diameter.

38. A method of treating a disease or condition in a subject in need of such treatment, comprising

delivering the drug from the osmotic delivery device of claim 35 to the subject at a substantially uniform rate for a period of about one month to about a year.

39. A method of manufacturing an osmotic delivery device comprising, loading the suspension formulation of claim 25 into a reservoir of the osmotic delivery device.